Study Shows Continued Weight Loss After Switching to Oral Wegovy Pills

Key Facts

1Real-world data showed patients switching from Wegovy or Zepbound injections to Wegovy pills continued to lose weight.

2Patients who stayed on the pill treatment for three months lost roughly 4% of their weight on average.

Real-world data showed patients switching from Wegovy or Zepbound injections to Wegovy pills continued to lose weight. CNBC reported that patients who stayed on the pill treatment for three months lost roughly 4% of their weight on average, highlighting the efficacy of the oral format in a non-clinical setting.

LLY closed at $1184.63 on September 29, 2026, as the market evaluates the transition toward more convenient oral administrations in the high-growth obesity drug category. The stock reached a day high of $1192.94 and a low of $1168.47 during that session.